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ABSTRACT 
Objective: The purpose of the present research work was to formulate and evaluate Terbinafine hydrochloride microsponges using quasi emulsion 
solvent diffusion technique and microsponge gel by using carbopol for controlled release of the drug and consequently avoiding its side effects.  
Methods: Microsponges containing Terbinafine hydrochloride were obtained successfully with six different drugs: polymer ratios. The formulations 
were studied for particle size, physical characterization, and in vitro release.  
Results: A selected THCI microsponge (MS IV) due to its better results when compared to other microsponge formulations were incorporated in 
different concentrations of carbopol and formulated as gels and evaluated for its pH, viscosity, spreadability, drug content, in vitro release, 
antifungal activity and in vivo studies. Among the four microsponge gel formulations, THMG II showed better results like pH 6.2, viscosity 3960 cps, 
spreadability 18.1 g cm/s, drug content of 87.6% and drug release showed fickian release pattern. The antifungal studies showed a zone of 
inhibition with 15.8 mm when compared to the pure drug, 19.2 mm, marketed formulation 16.0 mm and also showed better antifungal activity on 
fungal induced guinea pig skin when compared with control.  
Conclusion: In this study, we found that the controlled release of terbinafine hydrochloride from the microsponge gel reduced side effects and 
remarkably decreased gel application for fungal treatment.  
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Microsponges are porous, polymeric microspheres having a myriad of 
interconnected voids of particle size ranging from 5-150 µm. 
Microsponge Drug Delivery System (MDS) is a unique technology that 
provides controlled release of active ingredients [1-3]. They are mostly 
used for prolonged topical administration. Microsponges are designed to 
deliver pharmaceutical active ingredient efficiently at the minimum dose 
and also to enhance stability, reduce side effects and modify drug release 
profiles [4-7]. An MDS is highly cross-linked that acquire the flexibility to 
entrap a wide variety of active ingredients such as emollients, fragrances, 
sunscreens, essential oils, anti-infective, anti-fungal and anti-
inflammatory agents etc and are used as a topical carrier system. They 
can be incorporated into a conventional dosage form such as creams, 
lotions, gels, ointments, tablets, and powders and share a broad package 
of benefits and thus provides formulation flexibility [8-10]. 
The incidence of mycoses,, especially superficial fungal infections is 
increasing and according to a recent report, more than 25% of the 
world's population is affected [11, 12], disease progression is more 
rapid and severity increased in patients with compromised immune 
function [13].  
Terbinafine hydrochloride (THCI) is a broad-spectrum antifungal 
activity against a wide variety of fungi [14-16]. It is an ally amine 
antifungal used in the treatment of jock itch and athletes foot. It is 
highly lipophilic in nature and tends to accumulate in skin and nails 
when applied topically and cause side effects like rash, irritation etc. 
Because of the size and porous polymeric structure of microsponges, 
they slowly release the active ingredient, thereby prevent excess 
build up in epidermis and dermis and reduce side effects. 
Terbinafine hydrochloride (THCI) has Pharmacokinetic interactions 
with drugs that are substrates for CYP2D6 (e. g., tricyclic 
antidepressants, β-blockers, selective serotonin reuptake inhibitors 
[SSRIs], monoamine oxidase [MAO] inhibitors) [17, 18]. 
The aim of the present investigation was to design novel terbinafine 
hydrochloride microsponges (I-VI) with six different ratios of the 
drug: polymer, which acts as carriers for topical delivery of THCI. 
This investigation consisted of preparation, and evaluation of 
terbinafine hydrochloride microsponge gels (THMG) (I-IV), 
prepared by using the selected microsponges and different 
concentrations of carbopol, to obtain the cosmetically acceptable 
product for controlled drug release, prolonged duration of action 
and less side effects.  
MATERIALS AND METHODS 
Materials 
Terbinafine hydrochloride (THCI) was supplied as a gift sample from 
MSN Laboratories Ltd, Bollaram, India, Ethyl Cellulose, Polyvinyl 
alcohol, and Dichloromethane was purchased from SD Fine Chem 
Limited, Mumbai. Carbopol 940, Triethanolamine was purchased 
from Qualikems Fine Chem Pvt. Limited, Vadodara. Ethanol was 
purchased from Jiangsu Huax. International Trade Co. Ltd, China. 
PEG 400 purchased from Otto biochemical reagents, Mumbai. 
Preparation and characterization of THCl microsponges 
Preparation of the microsponges 
The microsponges containing Terbinafine hydrochloride (THCI) 
were prepared by quasi emulsion solvent diffusion method [19] 
using different drug: polymer ratios as shown in table 1. The inner 
phase Ethylcellulose was dissolved in dichloromethane and then 
added the drug to the solution under ultrasonication at 35 °C. The 
inner phase is then poured into the PVA solution in water. The 
resultant mixture was stirred at speed of 3000 rpm for 60 min and 
filtered to separate the microsponges. The microsponges were 
dried in a hot air oven at 40 °C for 12 h and weighed to determine 
the yield [20]. 
Characterization of THCl microsponges 
Fourier transforms infrared (FTIR) analysis 
FT-IR spectra of finely powdered pure terbinafine hydrochloride, 
Ethylcellulose as well as the THCl microsponge formulation were 
recorded on an FT-IR spectrophotometer (Shimadzu, Kyoto, 
Japan) by potassium bromide (KBr) disk pellet method [21]. 
Scanning electron microscopy (SEM) 
The morphology of microsponges was examined using a scanning 
electron microscope (GEOL 5400, USA) operating at 20 kV. Dried 
microspheres were coated with gold-palladium alloy for 45s under 
an argon atmosphere before observation. SEM photograph was 
recorded at a magnification of ×500 and 1500. 
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Table 1: Composition of the prepared THCl microsponge systems 
 Constituents  Microsponges formulation 
MS I MS II MS III MS IV MS V MS VI 
Terbinafine hydrochloride (g)  1  1  1  1  1  1 
Ethyl cellulose (g) 0.1 0.2 0.3 0.4 0.5 0.6 
Dichloromethane (ml)  5  5  5  5  5  5 
PVA (g) 0.05 0.05 0.05 0.05 0.05 0.05 
Distilled water (ml) 200 200 200 200 200 200 
 
Particle size studies 
Particle size analyses were performed on microsponge by laser light 
scattering technique using Mastersizer 2000 (Malvern Instruments 
Ltd., Worcestershire, UK). The result is the average of the three 
analyses. The values (D50) were expressed for all formulations as a 
mean size range [22]. 
Determination of loading efficiency 
The drug content in the microsponge was determined 
spectrophotometrically (λ max, 274 nm). A sample of terbinafine 
hydrochloride microsponges (10 mg) was dissolved in 100 ml of 
phosphate buffer, freshly prepared (pH 7.4). The drug content was 
calculated from the calibration curve and expressed as loading 
efficiency [23].  
Drug entrapment =
Mass of drug present in the microsponges
Theoretical mass of THCI
× 100 
Determination of production yield 
The production yield of the microsponge was determined by 
calculating accurately the initial weight of the raw materials and the 
last weight of the microsponge obtained [23]. 
Production yield =
Practical mass of microsponges
Theoretical mass (polymer + drug)
× 100 
Dissolution behavior of microsponges 
The drug release tests of the microsponges were carried out for 8 h at 
100 rpm by the paddle method. The temperature of the dissolution 
medium was controlled at 32±1 °C. The microsponges equivalent to 50 
mg of THCI were weighed. The dissolution medium was 150 ml of 
phosphate buffer (pH 7.4) to keep the sink condition for the drug. 
Three milliliters of the dissolution medium were sampled at certain 
intervals (0.5-8 h) and a fresh dissolution medium was simultaneously 
replaced in the apparatus to keep the volume constant. The withdrawn 
samples were filtered with a membrane filter (0.45 μm) and the 
filtrate was assayed spectrophotometrically at 274 nm. 
Preparation and characterization of terbinafine HCl 
microsponge gel 
Preparation of terbinafine hydrochloride microsponge gel 
(THMG) 
Four gels were prepared by using the best microsponge formulation 
and different concentrations of carbopol 940 as shown in table 2. An 
accurately weighed amount of carbopol 940 was taken and 
dissolved in water using the propeller. In another beaker, 
microsponges containing Terbinafine hydrochloride (free or 
entrapped, equivalent to 0.1%w/v) drug dissolved in ethanol and 
added to carbopol solution by stirring, followed by addition of PEG 
400. Neutralize the carbopol solution by slowly adding 
triethanolamine solution with constant stirring until the gel is 
formed. The pH of the final gel formed was determined [24]. 
Characterization of Terbinafine HCl microsponge gel 
Physical parameters of THMG 
Four gel formulations containing terbinafine hydrochloride 
microsponges were characterized for pH using pH meter, viscosity 
using a Brookfield digital viscometer (Model DV-III+Rheometer), 
spreadability and drug content [25-27]. 
 
Table 2: Formulation of gels containing THCI microsponges 
Ingredients THMG-I THMG-2 THMG-3 THMG-4 
Microsponge Eqv to THCl 0.1% w/v 1 1 1 1 
Carbopol 940(g) 0.25 0.35 0.45 0.55 
Ethanol(ml) 15 15 15 15 
PEG 400(g) 15 15 15 15 
Triethanolamine(g) 5 5 5 5 
Water up to (ml) 100 100 100 100 
 
In vitro release study 
The in vitro release of THMG formulations was studied by 
membrane diffusion technique using a cellophane membrane. The 
dissolution medium is pH7.4 phosphate buffer, freshly prepared. 
Cellophane membrane previously soaked overnight in the 
dissolution medium was tied to one end of a specifically designed 
glass cylinder (open at both ends). 1g of the formulation (equivalent 
to 1000 mg of Terbinafine hydrochloride) was accurately placed into 
this assembly. The cylinder was attached to stand and suspended in 
200 ml of dissolution medium maintained at 37±1 °C, the membrane 
just touching the receptor medium surface. The dissolution medium 
was stirred at 100 rpm speed using Teflon coated magnetic bead. 
Aliquots, each of 5 ml volume were withdrawn periodically at a 
predetermined time interval of 15, 30, 60, 120, 180, 240, 300, 360 
min and replaced by an equal volume of the receptor medium to 
maintain sink conditions. The aliquots were suitably diluted with the 
receptor medium and analyzed by UV-visible spectrophotometer at 
274 nm using neutralized phthalate buffer as blank [28]. 
Several mathematical models attempt to correlate dissolution 
profiles with the mechanisms of drug release from the drug 
delivery system [29, 30]. In this work, zero-order first order, 
Higuchi and Korsmeyer-Peppas models were applied to analyze 
the release profile of THCl from the prepared microsponge gels 
[31-35]. 
Antimicrobial activity 
This was determined by sabouraud dextrose medium employing 
“cup plate technique” using previously sterilized Petri dish. A 
Solution of the prepared gel formulation, marketed gel and pure 
terbinafine hydrochloride as a standard 1 mg/ml was poured into 
cups bored of size 8 mm into wells of sabouraud dextrose plate 
previously seeded with test organism (Candida albicans Procured 
from MTCC, Chandigarh, Acc. No.183). After allowing diffusion of 
solution for 2 h, the plates were incubated at 27 °C for 48 h. The 
zone of inhibition measured around each cup was compared with 
that of marketed gel and standard [36]. 
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In vivo study  
Male guinea pigs (250-350 g) were used. The hair was removed 
from their flanks with an electrical clipper. The area of skin (20 mm 
diameter) on each flank was scarified with coarse sandpaper. 
Scarified skin was infected with few drops of the culture of Candida 
albicans. Infected guinea pigs were housed individually in wire 
bottom cages and were provided food and water ad libitum. The 
fungal infection was induced on the guinea pig for the first 3 d, on 
the 4th day; the skin of guinea pig was scraped and was cultivated in 
sabouraud dextrose agar media plates. The inoculated plates were 
incubated at 27 °C for 48 h. The colonies were measured after 
incubation. On the 4th day, treatment was initiated by topical 
application to the infected sites with gel formulation for another 4 d. 
On the 8th and 11th day skin was again scraped and cultured on 
sabouraud dextrose agar plate respectively and further treatment 
was done. The inoculated plates were incubated at 27 °C for 48 h 
and examined for growth of colonies [36,37]. 
RESULTS AND DISCUSSION 
In the quasi-emulsion solvent diffusion method, the formation of 
microsponges could be by the rapid diffusion of dichloromethane (A 
good solvent for the polymer and drug) into the aqueous medium, 
might reduce the solubility of the polymer in the droplets, since the 
polymer was insoluble in water. The instant mixing of 
dichloromethane and water at the interface of the droplets induced 
precipitation of the polymer, thus forming a shell enclosing the 
dichloromethane and the dissolved drug. The finely dispersed 
droplets of the polymer solution of the drug were solidified in the 
aqueous phase via diffusion of the solvent [38]. 
FTIR spectra of pure Terbinafine hydrochloride, Ethylcellulose and 
mixture were shown in fig. 1, 2 and 3. Fundamental peaks of 
terbinafine It clearly indicates that the FTIR spectra of pure 




Fig. 1: FTIR spectra of Terbinafine hydrochloride 
 
 
Fig. 2: FTIR spectra of Ethylcellulose 
 
 
Fig. 3: FTIR spectra of microsponge formulation 
 
The scanning electron photograph of the microsponge is shown in fig. 4. 
It was observed by SEM analysis that the microsponges were finely 
spherical and uniform. Microscopy studies showed that THCI 
microsponges contained pores. The pores were induced by the diffusion 
of the solvent from the surface of the microparticles. The appearance of 
the particles was such that they were termed microsponges. 
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Fig. 4: SEM of THCI loaded microsponge formulation 
 
Changing drug: polymer ratio has a considerable effect on the size of 
the prepared THCI microsponge. Increasing the polymer fraction 
significantly increased the particle size as shown in table 3. This 
could probably be due to increasing the amount of polymer available 
per microsponge, hence larger particle size was obtained.  
The loading efficiency of terbinafine hydrochloride microsponge 
formulations is given in table 3. The loading efficiency calculated for all 
microsponges ranged from 85.5 to 92 %. The highest loading 
efficiency was found for the MS IV formulation, where a greater 
amount of drug was encapsulated. The production yield of Terbinafine 
hydrochloride microsponge formulations is given in table 3. 
Production yield calculated for all microsponges ranged from 65.75 to 
78.66 %. From the production yields of Terbinafine hydrochloride 
microsponge formulations, it was indicated that increasing the drug: 
polymer ratio to some extent increased the production yield. 
 
Table 3: Particle size, production yield and loading efficiency of THCI microsponges 
Formulation code Particle size (µm) Production yield (%) Drug loading (%) 
 MS I 43.8±0.15 65.75±0.45 85.5±0.64 
 MS II 44.8±0.34 67.33±0.54 86.5±0.32 
 MS III 45.6±0.65 68±0.76 90.5±0.54 
 MS IV 48.2±0.54 78.6±0.65 92±0.45 
 MS V 46.2±0.32 72.5±0.78 91.5±0.32 
 MS VI 48.5±0.43 70.57±0.24 90±0.45 
(mean±SD, n=3) 
 
The THCI release from the microsponge formulations is shown in fig. 
5 and table 4. The fig. shows that, generally, the release rate was 
high during the first two hours then the microsponges were able to 
sustain the release of THCI for more than 8 h in most formulations 
was shown in table 4. THCI release kinetics of microsponges on the 
basis of the highest r2 can be explained by Higuchi diffusion mode 
(data not shown). Based on the above characterization MS IV 
(having acceptable yield, particle size, high entrapment efficiency, 
and slow-release profile) was chosen as candidate formula and was 
subjected further in gel formulations. 
 
 
Fig. 5: Release profile of THCI microsponge formulations (Values are expressed as mean±SD, n=3) 
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Table 4: In vitro drug release studies of THCI microsponge formulations 
Time (h) Formulation code 
MS-1 MS-2 MS-3 MS-4 MS-5 MS-6 
0 0 0 0 0 0 0 
1 25.05±0.25 26.47±0.45 28.7±0.32 27.71±0.54 29.95±0.44 27.71±0.21 
2 28.51±0.21 33.18±0.76 34.19±0.75 38.03±0.74 35.63±0.26 38.03±0.55 
3 31.31±0.32 40.17±0.67 39.29±0.43 49.02±0.43 47.17±0.64 49.02±0.87 
4 37.16±0.63 51.06±0.55 49.06±0.32 65.24±0.54 55.12±0.47 65.24±0.81 
5 40.6±0.54 54.12±0.11 55.12±0.39 78.64±0.65 58.13±0.23 78.64±0.44 
6 53.01±0.43 60.06±0.43 63.17±0.76 80.13±0.25 69.35±0.75 80.13±0.57 
7 55.1±0.76 71.64±0.51 72.02±0.67 82.2±0.54 72.15±0.54 82.12±0.74 
8 58.83±0.96 73.19±0.76 79.23±0.89 85.67±0.75 74.78±0.55 85.67±0.53 
(mean±SD, n=3) 
 
The four gel formulations showed physical characteristics like 
spreadability, viscosity, pH and drug content, as given in table 5. The 
drug content of the formulations showed that the drug was 
uniformly distributed in the gels. 
 
Table 5: Spreadability, viscosity, pH and drug content of the formulated gels 
Formulation code Spreadability (g. cm/s) Viscosity(cps) pH Drug content (%) 
 THMG-I 17.62±0.13 3860±5 6.7±0.3 82.8±0.28 
 THMG-II 18.1±0.24 3960±4 6.2±0.2 87.6±0.87 
 THMG-III 16.53±0.26 4005±6 6.8±0.4 85.2±0.71 
 THMG-IV 15.8±0.18 4206±2 6.4±0.5 83.6±0.57 
 Marketed Formulation  18.3±0.33 3963±4 6.2±0.4 88.9±0.85 
(mean±SD, n=3) 
 
The in vitro release profile of four THCI microsponges gels was 
observed for 6 h and was depicted in fig. 6 and table 6. The total 
amount of drug release was 75.63%, 79.4%, 69.4%, 64.9% and 
84.8% observed at different time intervals for a period of 6 h for 
THMG I-IV and Marketed formulation (MF) respectively. The gel 
formulation (THMG II) showed the best release i.e. total amount of 
drug release was 79.4 %. From the logarithmic plot of the release 
data log Q versus log t of TMHG II, the diffusion exponent (n) and the 
kinetic constant (k) have been calculated, as shown in table 5. The 
results showed that n value of microsponges loaded gel is less than 
0.5. This indicates that the mechanism of drug release is Fickian 
diffusion, and is controlled by the porosity of the microsponges. 
 
 
Fig. 6: In vitro release profile of terbinafine hydrochloride from gel formulation (Values are expressed as mean±SD, n=3) 
 
Table 6: In vitro drug release studies of gel formulations 
Time (min) Formulation code 
MF THMG-1 THMG-2 THMG-3 THMG-4 
0 0 0 0 0 0 
15 18.3±0.29 17.5±0.23 17.6±0.31 18.5±0.54 19.3±0.45 
30 25.9±0.45 18.9±0.75 23.6±0.54 26.6±0.36 24.3±0.25 
60 32.1±0.76 28.4±0.85 29.6±0.43 31.6±0.76 28.6±0.73 
90 40.2±0.34 32.49±0.75 38.63±0.41 36.8±0.64 36.3±0.64 
180 55.3±0.65 46.55±0.53 47.3±0.74 43.3±0.83 42.6±0.87 
240 65.2±0.39 53.21±0.88 58.8±0.65 55.6±0.67 49.8±0.36 
300 71.13±0.76 64.21±0.59 69.3±0.27 63.3±0.87 55.8±0.64 
360 84.8±0.56 75.63±0.61 79.4±0.29 69.4±0.56 64.9±0.77 
(mean±SD, n=3) 
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Table 5: Kinetic treatment of the release data of THCI from microsponge loaded carbopol gel (THMG II) 





Antifungal activities for gels are shown in table 6. Formulation THMG II showed a zone of inhibition 15.8 mm in comparison with the marketed 
formulation and pure drug with 16.0 and 19.2 mm respectively. 
  
Table 6: Results of the antifungal study 






Pure drug 19.2±0.25 
Control ------ 
 (mean±SD, n=3) 
 
The results of the in vivo antifungal activity on guinea pig skin are 
shown in table 7. The fungal infection was induced on the guinea pig 
for the first 3 d, on the 4th day, the skin of guinea pig was scraped 
and was cultivated in sabouraud dextrose agar media plates and 
colony count was observed more than 50 for formulation THMG I-IV, 
MF and control respectively.  
The treatment of the gel formulation was started from 4th day 
applying for the next 4 d and studied with the effectiveness of gel on 
fungal inhibition. After 8th day the skin of the guinea pig was again 
scraped and checked for the growth of the colony in sabouraud 
dextrose agar plate. Colony count was observed 40, 30, 38, 35, 32 
and more than 50 for formulation THMG I-IV, MF, and control, 
respectively. Similarly, on the 11th day, the skin of guinea pig was 
again scraped and checked for the growth of the colony in 
sabouraud dextrose agar plate. Colony count was observed 21, 
13,19,15,12 and more than 50 for formulation THMG I-IV, MF, and 
control, respectively.  
Antifungal study and in vivo study results showed that formulation 
THMG II showed good inhibition of fungal infection in comparison 
with the marketed formulation and control. These studies were 
carried out in the Pharmacology laboratories of the College of 
Pharmaceutical Sciences, Andhra University which is approved by 
the institutional animal ethics committee and CPCSEA (Regd. No. 
516-01/A/CPCSEA) for experimentation on animals. 
 
Table 7: In vivo antifungal study on the guinea pig 
 Formulation Colonies 
4th day 8th day 11th day 
THMG-I >50 40 21 
THMG-II >50 30 12 
THMG-III >50 38 19 
THMG-IV >50 35 15 
MF >50 32 13 
Control >50 >50 >50 
 
 
8th day inhibition of colony after application of formulated gel THMG-II, marketed formulation and control. 
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11th day inhibition of colony after application of formulated gel THMG-I, marketed formulation and control. 
Fig. 7: In vivo antifungal study on the guinea pig skin 
 
CONCLUSION 
Microsponge based delivery system has been developed using quasi 
emulsion solvent diffusion method to provide a sustained release 
medication for topical delivery of Terbinafine Hydrochloride. The 
drug entrapment efficiency and the size of the prepared 
microsponges were affected by the drug: polymer ratio. 
Microsponge formulation MS IV which showed good results 
incorporated in different concentrations of carbopol and formulated 
as gels THMG I-IV. Among the four gels, THMG II showed better 
antifungal activity. A fickian diffusion which is controlled by the 
porosity of the microsponges is the mechanism of the drug release 
from the carbopol gel loaded with the selected microsponge 
formulation. As the gel has sustained-release characteristics the side 
effects have been minimized. 
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